United Therapeutics (UTHR) Debt to Equity (2017 - 2025)
Historic Debt to Equity for United Therapeutics (UTHR) over the last 14 years, with Q1 2025 value amounting to $0.03.
- United Therapeutics' Debt to Equity fell 7386.05% to $0.03 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.03, marking a year-over-year decrease of 7386.05%. This contributed to the annual value of $0.05 for FY2024, which is 6019.69% down from last year.
- Per United Therapeutics' latest filing, its Debt to Equity stood at $0.03 for Q1 2025, which was down 7386.05% from $0.05 recorded in Q4 2024.
- In the past 5 years, United Therapeutics' Debt to Equity registered a high of $0.23 during Q1 2021, and its lowest value of $0.03 during Q1 2025.
- For the 5-year period, United Therapeutics' Debt to Equity averaged around $0.15, with its median value being $0.16 (2023).
- In the last 5 years, United Therapeutics' Debt to Equity crashed by 1423.88% in 2021 and then tumbled by 7386.05% in 2025.
- Quarter analysis of 5 years shows United Therapeutics' Debt to Equity stood at $0.2 in 2021, then dropped by 17.47% to $0.17 in 2022, then decreased by 29.87% to $0.12 in 2023, then crashed by 60.2% to $0.05 in 2024, then plummeted by 36.89% to $0.03 in 2025.
- Its last three reported values are $0.03 in Q1 2025, $0.05 for Q4 2024, and $0.07 during Q3 2024.